BioTuesdays

Tag - BTIG

Accuray

BTIG ups Accuray to buy; PT $9.50

BTIG upgraded Accuray (NASDAQ:ARAY) to “buy” from “neutral,” with a price target of $9.50. The stock closed at $3.28 on Jan. 17. Last week, Accuray announced a compound annual growth rate revenue outlook of 8% to 12%...

Axsome Therapeutics

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

STAAR Surgical

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

NextCure

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

Alector

BTIG starts Alector at buy; PT $28

BTIG initiated coverage of Alector (NASDAQ:ALEC) with a “buy” rating and $28 price target. The stock closed at $15.80 on Nov. 20. Alector is focused on the immune system of the brain as a major player in...

Cerus

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

ASLAN Pharmaceuticals

BTIG cuts ASLAN Pharma to neutral; removes PT

BTIG downgraded ASLAN Pharmaceuticals (NASDAQ:ASLN) to “neutral” from “buy” without a price target after the company posted top-line data for Varlitinib, a pan-HER inhibitor, in its Phase 3 TREETOP study in second-line...

BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...

BTIG cuts Synlogic PT to $9 from $22

BTIG reduced its price target for Synlogic (NASDAQ:SYBX) to $9 from $22 after the company discontinued development of SYNB1020, an early-stage clinical product candidate for the treatment of hyperammonemia. The stock...

Subscribe

Sign up to our weekly BioTuesdays newsletter.